Antisense Therapeutics Limited

Isis Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Limited

Children's Hospital of Los Angeles

Antisense Therapeutic, Ltd

Ionis Pharmaceuticals, Inc.

Children's Hospital Los Angeles

George Tachas

C Frank Bennett

Kenneth W Dobie

Ravi Jain

Christopher Belyea

Mark Heffernan

Ety Klinger

Shoshi Tessler

Mark Paul Diamond

James G Karras

Jeffrey R Crosby

Christopher John Wraight

Hussein Hallak

Susan Gregory

Frank C Bennett

Lynne Maree Atley

Yong-Mi Kim

Hallak Hussein

The specification discloses a method of treating muscular disorders such as muscular dystrophy comprising periodically administering an inhibitory oligonucleotide to human CD49d ((the alpha 4 chain of VLA-4).

Therapeutic uses and methods

A method for treating a patient suffering from multiple sclerosis, including progressive forms of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE I to the patient, thereby treating the patient.

Methods for treating multiple sclerosis using antisense oligonucleotides

A method for mobilizing leukemia cells which are &#x3b1;4 integrin positive to the peripheral blood of a human subject, the method comprising administering to the human subject an effective amount of an antisense compound to &#x3b1;4 integrin. The cells may be mobilized from bone marrow. The antisense compound is: 5'-CUG AGTCTG TTTUCC AUUCU-3&#x2032; wherein, (a) each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester; (b) the nucleotides at the positions 1 to 3 from the 5&#x2032; end are 2&#x2032;-O-(2-methoxyethyl) modified ribonucleosides; (c) the nucleotides at the positions 4 to 12 from the 5&#x2032; end are 2&#x2032;-deoxyribonucleosides; (d) the nucleotides at the positions 13 to 20 from the 5&#x2032; end are 2&#x2032;-O-(2-methoxyethyl) modified ribonucleosides; and (e) all cytosines are 5-methylcytosines (C), or a pharmaceutically acceptable salt thereof.

Mobilizing leukemia cells

Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

Modulation of growth hormone receptor expression and insulin-like growth factor expression

The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.

Method for reducing circulating leukocytes in a human subject

Combination therapy

Provided herein are methods, compounds, and compositions for reducing expression of an IGF-IR mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions that inhibit expression of IGF-IR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate the tumor or cancer, or a symptom thereof.

Modulation of insulin like growth factor I receptor expression in cancer

A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin &#x3b1;4 comprising administering to the animal a composition comprising from. 0.001 to 1000 &#x3bc;g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin &#x3b1;4.

Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions

A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.

Growing community of inventors

Kew, Australia

George Tachas